Evidence map›Paper›PMID 31921687›Full record

ArticleFrontiers in oncology2019

Global, Regional, and National Burden of Endometrial Cancer, 1990-2017: Results From the Global Burden of Disease Study, 2017.

Shuang Zhang, Ting-Ting Gong, Fang-Hua Liu, Yu-Ting Jiang, Hui Sun, Xiao-Xin Ma, Yu-Hong Zhao, Qi-Jun Wu

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05427058 (Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management), which is not on this map. Cited by 120 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05427058 narecruitingnot on this mapstarted 2024, after this paper: background citation

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety

TypeinterventionalSponsorUniversity of BrawijayaRan2024 to 2026Enrolled36ConditionsCervical Cancer, Endometrial CancerArmsSuperior Hypogastric Plexus Block, Ganglion Impar Block
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  11. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.The New England journal of medicine · 2022
    Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuang ZhangDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Ting-Ting GongDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Fang-Hua LiuDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Yu-Ting JiangDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Hui SunDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Xiao-Xin MaDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Yu-Hong ZhaoDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.
Qi-Jun WuDepartment of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) is the most common malignancy affecting women in developed countries. Recently, the EC disease burden has changed; therefore, the Global Burden of Disease (GBD) 2017 was used to comprehensively analyze the global, regional, and national burden of EC between 1990 and 2017. General GBD cancer estimation methods were used with the data input from vital registration systems and cancer registries. Annual percent changes were calculated to quantify the trends of EC burden estimates during the study period. Furthermore, the sociodemographic index (SDI) was used to assess the relationship between the EC burden estimates and development level. From 1990 to 2017, the age-standardized incidence and prevalence rate of EC increased globally by 0.58 and 0.89% per year, respectively. In contrast, the age-standardized death rate and disability-adjusted-life years (DALYs) decreased by 1.19 and 1.21% per year, respectively. Increasing trends in both the incidence and prevalence were observed in all SDI quintiles, except for the low SDI quintiles, whereas decreasing trends were observed in all SDI quintiles for mortality and DALYs. Additionally, a non-linear association existed for the level of mortality rate, DALYs, and SDI. Of note, there was a strong positive association between a high body mass index and DALYs across all SDI quintiles. In conclusion, EC incidence and prevalence rates are growing globally, whereas the death rate and DALYs decreased between 1990 and 2017. Greater efforts, particularly detailed prevention strategies for reducing obesity, should be performed to reverse this phenomenon.

Indexed as

disability-adjusted life yearsdisease burdenendometrial cancerincidencemortalityprevalence

Identifiers

PMID31921687
PMCPMC6930915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.